ArticleJournal of endocrinological investigation2026
Association of first-trimester inflammatory markers with gestational diabetes mellitus subtypes and patterns: a cohort study.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the associations between first-trimester inflammatory markers and gestational diabetes mellitus (GDM), including its subtypes and patterns, and to explore the role of these markers in the early identification of GDM risk.
methodsThis cohort study included pregnant women aged ≥ 18 years and < 16 weeks of gestation, based on their first antenatal registration date, at a tertiary hospital from March to December 2023 retrospectively and from December 2023 to August 2024 prospectively. Inflammatory markers, calculated from peripheral blood cell counts, included the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and aggregated immune-inflammation index (AISI). Outcomes were GDM and its subtypes (isolated fasting hyperglycemia [IFH], isolated post-load hyperglycemia [IPH], and combined hyperglycemia [CH]), as well as patterns identified through latent class trajectory modeling based on blood glucose change during the OGTT.
resultsAmong 4,426 eligible women, 821 developed GDM. Elevated first-trimester NLR, SII, SIRI, and AISI were significantly associated with higher GDM risk. Compared with non-GDM pregnant women, these markers were positively associated with both IPH (ORs range: 1.16-1.22) and CH (ORs range: 1.28-1.54), but not IFH, and with two OGTT glucose trajectories (medium-speed increase-rapid decrease group [ORs range: 1.20-1.25] and rapid increase-slow decrease group [ORs range: 1.31-1.68]), while no significant associations were observed for the other two trajectories.
conclusionFirst-trimester inflammatory markers are associated with more severe GDM phenotypes and may serve as potential biomarkers to inform the early identification of higher-risk GDM phenotypes.
Indexed as
Identifiers
42082866What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.